Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Life Sciences AI ApplicationsAudio language not provided

Longevity biotech video description: what it says is proven in humans

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

At a glance

Automatic summary · not editorially reviewed

According to the video description, the video reviews longevity biotech category by category, focusing on what has been shown in a human body rather than mouse data or press releases. It names companies and trials and says Altos Labs, Retro Biosciences and Calico have no pipeline yet. [1]

  1. The description says the video looks at what has been shown in a human body so far, not mouse data or press releases. [1]

  2. The description says Altos Labs, Retro Biosciences and Calico have no pipeline yet. [1]

  3. The description calls Loyal's dog drug the most advanced program in the sector. [1]

Categories named in the description

The description lists the science in two parts: reprogramming, senolytics and NAD+ first, then rapamycin, metformin, plasma and clocks. It says the video ends with six categories and one scoreboard. The description does not report results for any of these categories, so it does not show what was proven in humans for them. [1]

Companies and trials listed

The description names Life Biosciences (ER-100), Unity Biotechnology, a 410-patient Parkinson's NAD+ trial, the PEARL rapamycin trial and the TAME metformin trial. It also names Altos Labs, Retro Biosciences, Calico, NewLimit, BioAge Labs, Insilico Medicine, Loyal (LOY-002), Isomorphic Labs and OpenAI/Retro's GPT-4b micro. It says Altos, Retro and Calico have no pipeline yet, calls NewLimit, BioAge and Insilico more credible trails, and calls Loyal's dog drug the most advanced program in the sector. No outcomes are given. [1]

Market size and stated purpose

The description says longevity biotech has raised billions of dollars and that the market size section invites viewers to pick a number. It presents the video as educational and informational only, not investment or medical advice, and says it is not affiliated with any named company. It also mentions two corrections, about Isomorphic Labs and the AI angle. [1]

Context & limits

Only the video description was available; the video and transcript were not reviewed. The description names categories, companies and trials but reports no results, so it cannot show what was proven in humans. Statements about pipelines and credibility are the creator's characterizations, not verified findings.

Based on the creator’s description; the full video and transcript were not analyzed.

[1] Longevity Biotech, Fact-Checked: What's Actually Proven So Far
Quoted passages in the original language
what's actually been shown in a human
Altos Labs, Retro Biosciences, Calico -- no
the most advanced program in the sector

About this video

Creator description · original textText language: English

Longevity biotech has raised billions of dollars, and the science is moving fast. This is a category-by-category look at what's actually been shown in a human body so far -- not the mouse data, not the press release. Chapters: 0:00 What's actually proven, category by category 0:18 The science, part one -- reprogramming, senolytics, NAD+ 0:59 The science, part two -- rapamycin, metformin, plasma & clocks 1:37 Six categories, one scoreboard 1:52 Who's building this 2:07 Altos Labs, Retro Biosciences, Calico -- no pipeline yet 2:39 NewLimit, BioAge Labs, Insilico Medicine -- the more credible trails 3:03 Loyal's dog drug -- the most advanced program in the sector 3:29 Two corrections -- Isomorphic Labs & the AI angle 4:05 The market size -- pick a number, any number 4:41 The honest last word Companies and trials referenced: Life Biosciences (ER-100), Unity Biotechnology, the 410-patient Parkinson's NAD+ trial, the PEARL rapamycin trial, the TAME metformin trial, Altos Labs, Retro Biosciences, Calico, NewLimit, BioAge Labs, Insilico Medicine, Loyal (LOY-002), Isomorphic Labs, and OpenAI/Retro's GPT-4b micro. The AI Briefing Book's sibling channel for life sciences -- get up to speed on AI and biotech, no hype, no jargon. ⚠️ Educational and informational only, not investment or medical advice. Not affiliated with any company named in this video. #Longevity #LongevityBiotech #AltosLabs #RetroBiosciences #Calico #AgingResearch #Biotech #LifeSciencesAI

Life Sciences AI Applications · 5 min · Source published: 2026-10-13

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…